DOCSLIB.ORG

Oncostatin M Contributes to Breast Tumor Metastasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oncostatin M Contributes to Breast Tumor Metastasis ONCOSTATIN M CONTRIBUTES TO BREAST TUMOR METASTASIS by Hunter J. Covert A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomolecular Sciences Boise State University May 2017 © 2017 Hunter J Covert ALL RIGHTS RESERVED BOISE STATE UNIVERSITY GRADUATE COLLEGE DEFENSE COMMITTEE AND FINAL READING APPROVALS of the dissertation submitted by Hunter J. Covert Dissertation Title: Oncostatin M Contributes To Breast Tumor Metastasis Date of Final Oral Examination: 14 April 2017 The following individuals read and discussed the dissertation submitted by student Hunter J. Covert, and they evaluated his presentation and response to questions during the final oral examination. They found that the student passed the final oral examination. Cheryl Jorcyk, Ph.D. Chair, Supervisory Committee Julia Thom Oxford, Ph.D. Member, Supervisory Committee Kenneth A Cornell, Ph.D. Member, Supervisory Committee Daniel Fologea, Ph.D. Member, Supervisory Committee Grant Trobridge, PhD External Examiner The final reading approval of the dissertation was granted by Cheryl Jorcyk, Ph.D., Chair of the Supervisory Committee. The dissertation was approved by the Graduate College. DEDICATION To my wife who has offered me so much support and convinced me to not give up numerous times during graduate school. This is also dedicated to my two young sons who keep me focused on the goals at hand and cheer me up whenever I am down. iv ACKNOWLEDGEMENTS I will start by acknowledging my mentor, Dr. Cheryl Jorcyk for letting me enter her lab in 2009 during my final semester as an undergraduate. Dr. Jorcyk taught me so many things during the time I spent in her lab. She taught me how become a better critical thinker in order to answer difficult scientific questions. She was always available for meetings to ensure progress was being made during my graduate studies. She has always been very supportive even when my ideas seemed a little far-fetched. The biggest thing that I am thankful for is Dr. Jorcyk helped build my confidence as a graduate student by always being very supportive. I very much would like to thank the members of my committee, Dr. Julie Oxford, Dr. Ken Cornell, and Dr. Daniel Fologea, who have contributed great ideas over the years. I would also like to thank Dr. Liliana Mellor, in Dr. Julie Oxford’s laboratory, who initially loaned our lab the antibody used for all of the CD44 western blotting, which began us on the trail of exploring CD44 in breast cancer. She also answered any questions we had throughout the last 5 years. I also want to acknowledge past and present members of the Jorcyk laboratory. Dr. Celeste Bolin, who taught me many molecular techniques and how to be a better critical thinker. Ken Tawara, M.S., who taught me everything about in vivo work and answered every question I’ve needed help with the last 8 years. Jake, Dollie, Jordan, and Danielle, who not only were tremendous team members in the lab, but also great friends. Hannah and Jackie deserve acknowledgement for helping with in vivo studies and also performing a lot of statistical analysis on large amounts of raw data. Nichole Ankenbrandt was extremely v helpful as an undergrad researcher who prepared a lot of the immunofluorescence used in my early graduate work. Raquel Brown at the Biomolecular Research Center for helping with confocal microscopy. Dr. Allan Albig for trusting me to use a lot of his equipment well after normal work hours. I also want to acknowledge Dr. Denise Wingett who is the director of the Biomolecular Science Graduate Program, as she has helped myself and others in our inaugural class, and the program in many ways. Finally, I would like to thank Beth Gee who is the Biomolecular Sciences Graduate Program coordinator. Being a member of the first class of a graduate program has been a learning experience for everyone involved, and Beth has always been there to support students and answer questions when needed. vi ABSTRACT The process of breast tumor metastasis has been examined to a great extent in recent years, but connecting specific protein-protein interactions to respective metastatic events remains challenging. The primary cause of death in patients with breast cancer is not from the primary tumor itself but rather from tumor metastases, which cause over 90% of all mortalities. In order for tumor cells to metastasize, they must undergo a phenotypic change known as the epithelial-mesenchymal transition (EMT). An EMT allows for the intravasation of tumor cells into nearby blood vessels or lymphatic channels. Once the primary tumor cells are within the network of vessels, they undergo a homing process to specific organs within the body. For breast cancer, secondary metastatic locations include the liver, brain, lung, and bone. It is known that signaling by proteins called cytokines influences breast tumor cells to adopt a more metastatic and aggressive phenotype. Cytokine signaling often changes protein functioning in the surrounding tumor environment and can lead to increased vasculature, which provides nutrients to a growing tumor, or phenotypic changes to individual cells on the invasive edge of a proliferating tumor. Transmembrane proteins, such as cluster of differentiation 44 (CD44), contribute to cell migration, cell detachment, and cellular docking during metastasis. The upregulation of CD44 expression by cytokine signaling is observed in less aggressive tumor cells, while more aggressive tumor cells constitutively express high basal levels of CD44. Both EMT and CD44 induced by cytokines are involved in metastasis during specifically timed events in the metastatic cascade. vii TABLE OF CONTENTS DEDICATION ................................................................................................................... iv ACKNOWLEDGEMENTS .................................................................................................v ABSTRACT ...................................................................................................................... vii LIST OF TABLES ............................................................................................................. xi LIST OF FIGURES .......................................................................................................... xii LIST OF ABBREVIATIONS .......................................................................................... xvi CHAPTER ONE: INTRODUCTION ..................................................................................1 Breast Cancer ...........................................................................................................1 Breast Cancer Subtypes ...............................................................................1 Metastatic Breast Cancer .............................................................................2 Oncostatin M (OSM) ...................................................................................3 Cluster of Differentiation 44 (Cd44) ............................................................5 Cancer Stem Cells (CSCs) and Breast Cancer Stem Cells (BCSCs) ...........7 Circulating Tumor Cells (CTCs) .................................................................8 In Vivo Models of Human Breast Cancer ....................................................8 Patient survival.............................................................................................9 Summary ..................................................................................................................9 CHAPTER TWO: OSM CONTRIBUTES TO BREAST CANCER METASTATIC POTENTIAL THROUGH CD44-INDUCED CELL MIGRATION AND DETACHMENT ................................................................................................................14 viii Abstract ..................................................................................................................15 Introduction ............................................................................................................16 Materials and Methods ...........................................................................................19 Cell Culture and Cytokine Stimulation ......................................................19 Immunofluorescence Staining and Microscopy.........................................19 qRT-PCR....................................................................................................20 Western Blot Analysis ...............................................................................20 Flow Cytometry .........................................................................................21 shRNA and Chemical Inhibitors ................................................................21 Detachment Assay .....................................................................................22 Scratch Assay .............................................................................................22 Results ....................................................................................................................23 OSM Induces Both CD44 Expression and Cleavage .................................24 OSM-Induced EMT is Independent of CD44 ............................................26 OSM-Induced Tumor Cell Detachment is Dependent on CD44 ...............27 OSM-Induced Tumor Cell Migration is Dependent on CD44...................28 Discussion ..............................................................................................................28
Load more

Recommended publications
  • A Model of Inflammatory Arthritis Highlights a Role for Oncostatin M In
    Available online http://arthritis-research.com/content/7/1/R57 ResearchVol 7 No 1 article Open Access A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL Wang Hui1, Tim E Cawston1, Carl D Richards2 and Andrew D Rowan1 1Musculoskeletal Research Group, The Medical School, University of Newcastle, Newcastle upon Tyne, UK 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Corresponding author: Andrew D Rowan, [email protected] Received: 21 Jul 2004 Revisions requested: 20 Sep 2004 Revisions received: 5 Oct 2004 Accepted: 11 Oct 2004 Published: 10 Nov 2004 Arthritis Res Ther 2005, 7:R57-R64 (DOI 10.1186/ar1460)http://arthritis-research.com/content/7/1/R57 © 2004 Hui et al., licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 2.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is cited. Abstract Oncostatin M is a pro-inflammatory cytokine previously shown to RANK and its ligand RANKL in the inflammatory cells, in promote marked cartilage destruction both in vitro and in vivo inflamed synovium and in articular cartilage of knee joints treated when in combination with IL-1 or tumour necrosis factor alpha. with the cytokine combinations compared with expression in However, the in vivo effects of these potent cytokine joints treated with the cytokines alone or the control. This model combinations on bone catabolism are unknown. Using of inflammatory arthritis demonstrates that, in vivo, oncostatin M adenoviral gene transfer, we have overexpressed oncostatin M in combination with either IL-1 or tumour necrosis factor alpha in combination with either IL-1 or tumour necrosis factor alpha represents cytokine combinations that promote bone intra-articularly in the knees of C57BL/6 mice.
    [Show full text]
  • Oncostatin M Exhibit Elevated Responsiveness to IL-31 Receptor
    IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M This information is current as Janine Bilsborough, Sherri Mudri, Eric Chadwick, Brandon of September 28, 2021. Harder and Stacey R. Dillon J Immunol 2010; 185:6023-6030; Prepublished online 18 October 2010; doi: 10.4049/jimmunol.0902769 http://www.jimmunol.org/content/185/10/6023 Downloaded from References This article cites 29 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/185/10/6023.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M Janine Bilsborough,1 Sherri Mudri,1 Eric Chadwick,2 Brandon Harder,3 and Stacey R. Dillon IL-31 signals through the heterodimeric receptor IL-31RA and oncostatin M receptor (OSMR), and has been linked with the development of atopic dermatitis, a Th2 cytokine-associated disease in humans.
    [Show full text]
  • Respiratory Viral Infection Function for Innate Defense Against Airway Epithelial Versus Immune Cell Stat1
    Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection This information is current as Laurie P. Shornick, Audrey G. Wells, Yong Zhang, Anand of September 27, 2021. C. Patel, Guangming Huang, Kazutaka Takami, Moises Sosa, Nikhil A. Shukla, Eugene Agapov and Michael J. Holtzman J Immunol 2008; 180:3319-3328; ; doi: 10.4049/jimmunol.180.5.3319 Downloaded from http://www.jimmunol.org/content/180/5/3319 Supplementary http://www.jimmunol.org/content/suppl/2008/02/20/180.5.3319.DC1 Material http://www.jimmunol.org/ References This article cites 47 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/180/5/3319.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection1 Laurie P.
    [Show full text]
  • Oncostatin M Is a Proinflammatory Mediator. in Vivo Effects Correlate with Endothelial Cell Expression of Inflammatory Cytokines and Adhesion Molecules
    Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. V Modur, … , G A Zimmerman, T M McIntyre J Clin Invest. 1997;100(1):158-168. https://doi.org/10.1172/JCI119508. Research Article Oncostatin M is a member of the IL-6 family of cytokines that is primarily known for its effects on cell growth. Endothelial cells have an abundance of receptors for oncostatin M, and may be its primary target. We determined if oncostatin M induces a key endothelial cell function, initiation of the inflammatory response. We found that subcutaneous injection of oncostatin M in mice caused an acute inflammatory reaction. Oncostatin M in vitro stimulated: (a) polymorphonuclear leukocyte (PMN) transmigration through confluent monolayers of primary human endothelial cells; (b) biphasic PMN adhesion through rapid P-selectin expression, and delayed adhesion mediated by E-selectin synthesis; (c) intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 accumulation; and (d) the expression of PMN activators IL-6, epithelial neutrophil activating peptide-78, growth-related cytokine alpha and growth-related cytokine beta without concomitant IL-8 synthesis. The nature of the response to oncostatin M varied with concentration, suggesting high and low affinity oncostatin M receptors independently stimulated specific responses. Immunohistochemistry showed that macrophage-like cells infiltrating human aortic aneurysms expressed oncostatin M, so it is present during a chronic inflammatory reaction. Therefore, oncostatin M, but not other IL-6 family members, fulfills Koch's postulates as an inflammatory mediator. Since its effects on endothelial cells differ significantly from established mediators like TNFalpha, it may uniquely contribute to the inflammatory cycle.
    [Show full text]
  • Oncostatin M Regulation of Inflammatory Responses By
    Regulation of Inflammatory Responses by Oncostatin M Philip M. Wallace,1,2* John F. MacMaster,† Katherine A. Rouleau,† T. Joseph Brown,* James K. Loy,† Karen L. Donaldson,3* and Alan F. Wahl3* Oncostatin M (OM) is a pleiotropic cytokine produced late in the activation cycle of T cells and macrophages. In vitro it shares properties with related proteins of the IL-6 family of cytokines; however, its in vivo properties and physiological function are as yet ill defined. We show that administration of OM inhibited bacterial LPS-induced production of TNF-a and lethality in a dose-dependent manner. Consistent with these findings, OM potently suppressed inflammation and tissue destruction in murine models of rheumatoid arthritis and multiple sclerosis. T cell function and Ab production were not impaired by OM treatment. Taken together these data indicate the activities of this cytokine in vivo are antiinflammatory without concordant immunosuppression. The Journal of Immunology, 1999, 162: 5547–5555. he normal development of an inflammatory response must from the inflammatory effector phase back to homeostasis also are be rapidly followed by the engagement of a feedback sys- being evaluated for their clinical potential as drugs. The cytokines T tem to minimize adventitious tissue damage and regulate IL-10 and IL-11 both appear to accelerate this process and their the eventual return to homeostasis. This system involves a multi- administration have proven effective in resolving several animal tude of regulators including cytokines, adhesion molecules, pro- models of chronic inflammatory disease (10). teases, corticosteroids, and subsequent regulators of each of these Oncostatin M (OM)4 is a pleiotropic cytokine that is produced agents.
    [Show full text]
  • Potential Target Genes (Whole List)
    Potential target genes (whole list) 1. MGC3200 hypothetical protein MGC3200, LocusLink=84265 2. FLJ20277 hypothetical protein FLJ20277, LocusLink=55624 3. POU2F1 POU domain, class 2, transcription factor 1, LocusLink=5451 4. EFNA3 ephrin-A3, LocusLink=1944 5. OAZ3 ornithine decarboxylase antizyme 3, LocusLink=51686 6. FLJ20139 hypothetical protein FLJ20139, LocusLink=54833 7. ARHC ras homolog gene family, member C, LocusLink=389 8. CRABP2 cellular retinoic acid-binding protein 2, LocusLink=1382 9. SIAT6 sialyltransferase 6 (N-acetyllacosaminide alpha 2,3-sialyltransferase) 10. FLJ13181 hypothetical protein FLJ13181, LocusLink=80263 11. TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator); 12. NUF2R hypothetical protein NUF2R, LocusLink=83540 13. PTAFR platelet-activating factor receptor, LocusLink=5724 14. LOC57147 hypothetical protein LOC57147, LocusLink=57147 15. GFI1 growth factor independent 1, LocusLink=2672 16. FLJ11220 hypothetical protein FLJ11220, LocusLink=54665 17. KIAA0673 KIAA0673 protein, LocusLink=23128 18. FLJ23323 hypothetical protein FLJ23323, LocusLink=79707 19. CEZANNE zinc finger protein Cezanne, LocusLink=56957 20. KIAA0736 KIAA0736 gene product, LocusLink=9900 21. KIAA0761 Mid-1-related chloride channel 1, LocusLink=23155 22. DD96 epithelial protein up-regulated in carcinoma, membrane associated protein 17 23. DDOST dolichyl-diphosphooligosaccharide-protein glycosyltransferase, LocusLink=1 24. FLJ10349 hypothetical protein FLJ10349, LocusLink=54707 25. FLJ12455 hypothetical protein FLJ12455, LocusLink=63906 26. DKFZP564D0478 hypothetical protein DKFZp564D0478, LocusLink=84065 27. NCF2 neutrophil cytosolic factor 2 (65kD, chronic granulomatous disease, autosomal 2) 28. AP4B1 adaptor-related protein complex 4, beta 1 subunit, LocusLink=10717 29. ASML3B acid sphingomyelinase-like phosphodiesterase, LocusLink=27293 30. CLASPIN homolog of Xenopus Claspin, LocusLink=63967 31. FLJ20435 hypothetical protein FLJ20435, LocusLink=54933 32.
    [Show full text]
  • Crystal Structure and Functional Dissection of the Cytostatic Cytokine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Research Article 863 Crystal structure and functional dissection of the cytostatic cytokine oncostatin M Marc C Deller1,2†#, Keith R Hudson2‡#, Shinji Ikemizu1, Jerónimo Bravo1§, E Yvonne Jones1* and John K Heath2 Background: The cytokine oncostatin M (OSM) inhibits growth of Addresses: 1Cancer Research Campaign Receptor certain tumour-derived cells, induces proliferation in other cell types Structure Group, Division of Structural Biology, The Wellcome Trust Centre for Human Genetics, (e.g. haemangioblasts) and is a mediator of inflammatory responses. Its University of Oxford, Roosevelt Drive, Oxford OX3 mechanism of action is via specific binding to gp130 and either the leukaemia 7BN, UK and 2Cancer Research Campaign Growth inhibitory factor receptor (LIFR) or oncostatin M receptor (OSMR) systems Factors Group, School of Biochemistry, University of at the cell surface to form an active signalling complex. Birmingham, Edgbaston, Birmingham B15 2TT, UK. Present addresses: †Yale University School of Results: We report here the crystal structure of human oncostatin M (hOSM) Medicine, Department of Pharmacology, Sterling along with mutagenesis data which map the receptor-binding epitopes of the Hall of Medicine, PO Box 208066, New Haven, molecule. The structure was determined to a resolution of 2.2 Å and conforms CT 06520-8066, USA, ‡Genesis Research and to the haematopoietin cytokine up-up-down-down four-helix bundle topology. Development, 1 Fox Street, Parnell, Auckland, New Zealand and §Laboratory of Molecular Biology, The site 2 epitope, responsible for gp130 binding, is centred around Gly120 Medical Research Council Centre, Hills Road, which forms a ‘dimple’ on the surface of the molecule located on helices A and Cambridge CB2 2QH, UK.
    [Show full text]
  • Oncostatin M Suppresses Activation of IL-17/Th17 Via SOCS3 Regulation in CD4+ T Cells
    Oncostatin M Suppresses Activation of IL-17/Th17 via SOCS3 Regulation in CD4 + T Cells This information is current as Hye-Jin Son, Seung Hoon Lee, Seon-Yeong Lee, of September 28, 2021. Eun-Kyung Kim, Eun-Ji Yang, Jae-Kyung Kim, Hyeon-Beom Seo, Sung-Hwan Park and Mi-La Cho J Immunol published online 16 January 2017 http://www.jimmunol.org/content/early/2017/01/15/jimmun ol.1502314 Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Errata An erratum has been published regarding this article. Please see next page or: /content/198/12/4879.full.pdf The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 16, 2017, doi:10.4049/jimmunol.1502314 The Journal of Immunology Oncostatin M Suppresses Activation of IL-17/Th17 via SOCS3 Regulation in CD4+ T Cells Hye-Jin Son,*,1 Seung Hoon Lee,*,1 Seon-Yeong Lee,*,1 Eun-Kyung Kim,* Eun-Ji Yang,* Jae-Kyung Kim,* Hyeon-Beom Seo,* Sung-Hwan Park,*,2 and Mi-La Cho*,†,2 Oncostatin M (OSM) is a pleiotropic cytokine and a member of the IL-6 family.
    [Show full text]
  • Hippo Signaling Interactions with Wnt/Β-Catenin and Notch Signaling Repress Liver Tumorigenesis
    The Journal of Clinical Investigation RESEARCH ARTICLE Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis Wantae Kim,1,2 Sanjoy Kumar Khan,1,2 Jelena Gvozdenovic-Jeremic,1 Youngeun Kim,3 Jason Dahlman,1 Hanjun Kim,1,2 Ogyi Park,4 Tohru Ishitani,5 Eek-hoon Jho,3 Bin Gao,4 and Yingzi Yang1,2 1Genetic Disease Research Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA. 2Department of Developmental Biology, Harvard School of Dental Medicine (HSDM), Boston, Massachusetts, USA. 3Department of Life Sciences, University of Seoul, Seoul, South Korea. 4Section on Liver Biology, National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, Bethesda, Maryland, USA. 5Division of Cell Regulation Systems, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. Malignant tumors develop through multiple steps of initiation and progression, and tumor initiation is of singular importance in tumor prevention, diagnosis, and treatment. However, the molecular mechanism whereby a signaling network of interacting pathways restrains proliferation in normal cells and prevents tumor initiation is still poorly understood. Here, we have reported that the Hippo, Wnt/β-catenin, and Notch pathways form an interacting network to maintain liver size and suppress hepatocellular carcinoma (HCC). Ablation of the mammalian Hippo kinases Mst1 and Mst2 in liver led to rapid HCC formation and activated Yes-associated protein/WW domain containing transcription regulator 1 (YAP/TAZ), STAT3, Wnt/β-catenin, and Notch signaling. Previous work has shown that abnormal activation of these downstream pathways can lead to HCC. Rigorous genetic experiments revealed that Notch signaling forms a positive feedback loop with the Hippo signaling effector YAP/TAZ to promote severe hepatomegaly and rapid HCC initiation and progression.
    [Show full text]
  • Molecular Signatures Differentiate Immune States in Type 1 Diabetes Families
    Page 1 of 65 Diabetes Molecular signatures differentiate immune states in Type 1 diabetes families Yi-Guang Chen1, Susanne M. Cabrera1, Shuang Jia1, Mary L. Kaldunski1, Joanna Kramer1, Sami Cheong2, Rhonda Geoffrey1, Mark F. Roethle1, Jeffrey E. Woodliff3, Carla J. Greenbaum4, Xujing Wang5, and Martin J. Hessner1 1The Max McGee National Research Center for Juvenile Diabetes, Children's Research Institute of Children's Hospital of Wisconsin, and Department of Pediatrics at the Medical College of Wisconsin Milwaukee, WI 53226, USA. 2The Department of Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA. 3Flow Cytometry & Cell Separation Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, USA. 4Diabetes Research Program, Benaroya Research Institute, Seattle, WA, 98101, USA. 5Systems Biology Center, the National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, MD 20824, USA. Corresponding author: Martin J. Hessner, Ph.D., The Department of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI 53226, USA Tel: 011-1-414-955-4496; Fax: 011-1-414-955-6663; E-mail: [email protected]. Running title: Innate Inflammation in T1D Families Word count: 3999 Number of Tables: 1 Number of Figures: 7 1 For Peer Review Only Diabetes Publish Ahead of Print, published online April 23, 2014 Diabetes Page 2 of 65 ABSTRACT Mechanisms associated with Type 1 diabetes (T1D) development remain incompletely defined. Employing a sensitive array-based bioassay where patient plasma is used to induce transcriptional responses in healthy leukocytes, we previously reported disease-specific, partially IL-1 dependent, signatures associated with pre and recent onset (RO) T1D relative to unrelated healthy controls (uHC).
    [Show full text]
  • Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant
    Research Article Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant Meiyun Fan,1 Pearlly S. Yan,2 Cori Hartman-Frey,1 Lei Chen,1 Henry Paik,1 Samuel L. Oyer,1 Jonathan D. Salisbury,1 Alfred S.L. Cheng,2 Lang Li,3 Phillip H. Abbosh,1 Tim H-M. Huang,2 and Kenneth P. Nephew1,4,5 1Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana; 2Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; 3Division of Biostatistics, Department of Medicine and 4Department of Cellular and Integrative Physiology, Indiana University School of Medicine; and 5Indiana University Cancer Center, Indianapolis, Indiana Abstract Introduction The development of targeted therapies for antiestrogen- The steroid hormone estrogen is strongly implicated in the resistant breast cancer requires a detailed understanding development and progression of breast cancer (1). The primary of its molecular characteristics. To further elucidate the mediator of estrogen action in breast cancer cells is estrogen molecular events underlying acquired resistance to the receptor a (ERa), a ligand-activated transcription factor (1). antiestrogens tamoxifen and fulvestrant, we established Consequently, the leading drugs used for endocrine therapy of drug-resistant sublines from a single colony of hormone- breast cancer all block ERa activity, including antiestrogens (i.e., dependent breast cancer MCF7 cells. These model systems tamoxifen and fulvestrant) and aromatase inhibitors (2). Despite allowed us to examine the cellular and molecular changes the efficacy and favorable safety profile of these agents, the use of induced by antiestrogens in the context of a uniform clonal endocrine therapy is limited by the onset of drug resistance, in background.
    [Show full text]
  • Anti-Interferon-Alpha/Beta Receptor 1 (I4902)
    Anti-Interferon-/ Receptor 1 produced in goat, affinity isolated antibody Catalog Number I4902 Synonym: Anti-IFN-/ R1 IFN/R1 is very responsive to type I interferons and bind to IFN- and IFN- subtypes. It is also functionally Product Description involved in signal transduction because of its Anti-Interferon-/ Receptor 1 is produced in goat using association with the cytoplasmic tyrosine kinase JAK1.4 as immunogen a purified recombinant human The type I interferons, and , are produced by interferon-/ receptor 1 extracellular domain, leukocytes ( subunits), fibroblasts ( subtypes), expressed in Sf21 insect cells. Affinity isolated antibody lymphocytes ( subtypes), and ruminant embryos is obtained from goat anti-IFN/R1 antiserum by (subtypes).5 Interferon receptors are generally found on immunospecific purification which removes essentially most human cell types whatever their origin, even on all goat serum proteins, including immunoglobulins, cells poorly responsive to interferon. IFN/R1 is which do not specifically bind to the peptide. expressed on the cell surface in a variety of human cell lines.1 Anti-Interferon-/ Receptor 1 recognizes recombinant human IFN-/ R by various immunochemical Reagent techniques including immunoblotting and flow Lyophilized from 0.2 m-filtered solution in phosphate cytometry. Based on immunoblotting, this antibody buffered saline containing carbohydrates. shows no cross-reactivity with recombinant human IFN- RI and IFN- RII. Immunoblotting of lysates from Precautions and Disclaimer a variety of human cell lines showed that IFN/R1 has This product is for R&D use only, not for drug, an apparent molecular mass of 135 kDa.1 household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe IFN/R1 is a member of the cytokine receptor handling practices.
    [Show full text]